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SHORT COMMUNICATION
Reduction of interstitial fluid pressure after TNF-oa treatment of three
human melanoma xenografts
CA Kristensen, M Nozue, Y Boucher and RK Jain
Edwin L Steele Laboratory, Harvard Medical School, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114,
USA.
Summary Tumour necrosis factor-a (TNF-a) reduced the interstitial fluid pressure (IFP) to 54-64%
(P<0.05) and the mean arterial blood pressure (MABP) to 70% (P<0.01) of control values after 5 h in three
human melanoma tumour lines transplanted to nude mice.
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Tumour necrosis factor-a (TNF-a) or cachectin has been
proposed as a potential anti-cancer agent for clinical
application owing to a remarkable activity of this biological
response modifier against several types of murine neoplasms
(Asher et al., 1987). Furthermore, TNF-a seems to play an
important vasodilatory role in host response to septic insults
(Tracey et al., 1987), potentially mediated by the release of
nitric oxide (NO) from endothelial cells or macrophages
(Baudry and Vicaut, 1993; Kilbourn et al., 1990). The
combination of TNF-a, melphalan and interferon-y in
regional perfusion of human extremity sarcomas and
melanomas has resulted in impressive response rates
(Vaglini et al., 1994; Lienard et al., 1992), presumably
owing to a combined early effect on tumour vasculature
and a possible immune enhancement effect of TNF-a (Fraker
and Alexander, 1993). A relationship between production of
vascular endothelial growth factor (VEGF) and TNF-a
cytotoxicity has been demonstrated in vivo, supporting the
hypothesis of a vascular effect of TNF-a on tumour tissue
(Amikura et al., 1995). Several studies have suggested that
increased delivery of macromolecules (e.g. protein-bound
chemotherapeutic agents, antibodies and DNA) can be
achieved by lowering the interstitial fluid pressure (IFP)
(Boucher and Jain, 1992; Boucher et al., 1991; Kristjansen et
al., 1993; Zlotecki et al., 1993, 1995). The present study was
initiated in order to elucidate whether TNF-a can reduce
tumour IFP.
Materials and methods
Tumour lines
Three human melanoma cell lines (S-MEL, P-MEL and
MeWo) were established in vivo by subcutaneous injection
into the flank of male nude mice. S-MEL and P-MEL cells
were kindly supplied by Dr DL Fraker, NIH, Bethesda, MD,
USA. These two tumour lines were isolated from peripheral
melanomas of two patients responding to isolated limb
perfusion with TNF-a, melphalan and interferon-y. Tumours
for experiments were established by placing 1 mm3 of donor
tumour tissue subcutaneously (s.c.) in the right hind leg of
nude mice under ketamine/xylazine (100:10 mg kg-' body
weight s.c.) anaesthesia. Experiments were performed when
the tumours reached a size of approximately 225 mm'.
Received 12 December 1995; revised 20 March 1996; accepted 27
March 1996
Mean arterial blood pressure
Cannulation of the left carotid artery was performed after a
longitudinal skin incision above the trachea. After removal of
the submandibular gland, the paratracheal muscles were split
and the left carotid artery was isolated. The cranial end of
the artery was ligated with a 6-0 silk suture and another
suture was tied loosely around the central part of the artery.
A metal clamp was positioned caudally to stop the blood
flow during the cannulation. A polyethylene catheter (PE-10;
Becton-Dickinson, Sparks, MD, USA) filled with heparinised
saline was inserted through a hole cut proximally to the
cranial ligature, and the other suture was tied tightly around
the tubing and artery. The clamp was removed and the end
of the tubing was connected to a pressure transducer as
described previously (Zlotecki et al., 1993).
Interstitialfluid pressure
IFP was measured with the wick-in needle (WIN) technique
as described by Boucher et al., 1991. Fluid communication
between the needle and the pressure transducer was ensured
by compression and decompression of the tubing in each
experiment. During IFP measurements, the body temperature
ofeach mouse was kept at approximately 35°C by placing the
mouse on a 37°C heating pad.
Arterial blood gas analysis
At the end of each experiment, the arterial tubing was cut
close to the artery, and after allowing 2-3 drops to pass,
arterial blood was collected in a heparinised glass capillary
tube and analysed immediately in a blood gas analyser (ABL
330, Radiometer, Copenhagen, Denmark).
Experimental setup
TNF-a (500 Mg kg-') or sodium chloride (0.9%) was injected
in the tail vein of the mice. After 5 or 24 h each mouse was
anaesthetised with ketamine/xylazine (100: 10 mg kg-' body
weight) and measurements of IFP, mean arterial blood
pressure (MABP) and respiration rate (RR) as well as
arterial blood gas analysis were performed. In a separate
experiment, the effect of TNF-a on the different parameters
within the first 30 min to 1 h was studied by tail vein
injection of TNF-a (500 ,g kg-') or sodium chloride (0.9%)
after determination of initial MABP and IFP. Thus, the
MABP and IFP could be followed during the following 30-
60 min and compared with the initial values before injection.
In all experiments, the fluid communication was checked atEffect of TNF-ax on interstitial fluid pressure
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regular intervals. Each experiment was terminated when the
fluid communication could no longer be maintained.
Statistical analysis
Data obtained 5 and 24 h after injection of TNF-a were
compared with controls by a two-way analysis of variance
(ANOVA, SPSS 6.0), allowing comparison of the effect of
TNF-a and time (5 and 24 h) on the measured parameters.
Data obtained from the same tumour at three time points
(before, 30 and 60 min after TNF-ax injection) were compared
with controls by an analysis of variance between repeated
measures (MANOVA, SPSS 6.0). Tumour sizes were
compared by an independent samples t-test (SPSS 6.0).
Results
A total of 121 tumours were studied. The mean tumour size
was 222+72 mm3 and 231 +51 mm3 in treated and non-
treated tumours respectively (P=0.39). No correlation was
found between tumour size and IFP by linear curve fitting of
the data (r2 =0.06). IFP in untreated tumours varied between
1.6 and 28.5 mmHg, mean IFP was 14+6.5 (s.d.), and there
was no difference in pretreatment IFP between tumour types
(P=0.21). TNF-oa induced no significant difference in MABP
or IFP during the first hour after injection compared with
control animals (Table I). IFP and MABP in the three
tumour lines at 5 and 24 h after TNF-a or sodium chloride
injection are also shown in Table I. In the 5 h experiments,
TNF-a reduced tumour IFP to 50-70% of control values in
all three tumour lines (P<0.05). This reduction coincided
with a (30%) decrease in MABP (P<0.01) (Table II). At
24 h, the pressure lowering effect of TNF-c was no longer
present in any of the examined melanoma lines (Table I).
Data from the arterial blood gas analysis are shown in
Table II. Plasma pH, pCO2 and [HCO3-] were significantly
decreased in tumours 5 h after TNF-ax injection. No changes
were found in P02 or respiration rate at any of the examined
time points.
Discussion
The movement of molecules across vessel walls and in the
interstitial matrix occurs by diffusion and convection.
Convection results from a pressure gradient between the
blood vessels and the tumour cells. Transport of low
molecular weight substances is diffusion dominated, and
delivery of small molecules can probably be increased by
making the blood flow more uniform (Jain, 1994).
Convection becomes important at higher molecular weights
(e.g. albumin-bound drugs, antibodies or genes (Jain, 1994)
and depends mainly on the pressure gradients between the
vascular and interstitial space and the hydraulic conductivity
(K). The equilibration of microvascular and interstitial
pressures in tumours reduces the movement of large
molecules by convection (Boucher and Jain, 1992).
The present study is the first to investigate the relation-
ship between TNF-a and tumour interstitial fluid pressure in
human melanoma xenografts. Melanomas are particularly
interesting in this context, since clinical studies have shown
impressive effects of the combination of TNF-a with
melphalan and interferon-y in locally perfused melanomas
(Fraker and Alexander, 1993; Vaglini et al., 1994). The
mean IFP of untreated tumours was 14 mmHg, which is
directly comparable with previously obtained clinical
melanoma data (mean IFP = 14.3) (Boucher et al., 1991).
Other investigators have studied IFP in human melanoma
xenografts and have found comparable baseline IFP values
with no correlation between IFP and tumour size (Curti et
al., 1993; Tufto and Rofstad, 1995). In one clinical study,
however, IFP increased with melanoma size (Boucher et al.,
1991).
TNF-ax decreased IFP significantly in all of the three
examined tumour lines 1-5 h after TNF-a injection (Table
I). The animals in the 1 h experiment were treated differently
from the animals in which the IFP was measured 5 and 24 h
after TNF-a treatment, since the former animals were
anaesthetised and the IFP measurement was already
initiated when the tail vein injection was given. In the 5
and 24 h experiments the animals were restrained and
injected 5 or 24 h before the IFP measurement. It might
seem as if the IFP increases between the 1 h and 5 h control
groups, but there is significant overlap between the data and
no significant difference between the pretreatment and 5 h
IFP values in any of the control groups. A general
relationship between MABP and IFP has previously been
demonstrated (Zlotecki et al., 1993, 1995), and the
microvascular pressure has been found to be the main
driving force of IFP in solid tumours (Boucher and Jain,
1992). An increase in drug delivery requires an increase in
transvascular pressure gradient and not only a drop in IFP
(Netti et al., 1995). The present decrease in MABP
Table I IFP measurements during the first 60min after tail vein injection of TNF-a (500S gkg') and at S and 24h after
TNF-a injection
MeWo P-MEL S-MEL
Sodium Sodium Sodium
IFP (mmHg) chloride TNF-ox chloride TNF-oa chloride TNF-ac
Pretreatment 11.5 12 14.5 14.5 17 15
(6) (5) (4.5) (9.5) (3.5) (6.5)
n=8 n=5 n=4 n=6 n=6 n=7
30min 14 14.5 13 16 18.5 13
(6) (7.5) (4.5) (10) (4) (6.5)
n=8 n=S n=4 n=6 n=5 n=7
60min 14.5 12 12 13.5 15.5 12.5
(7.5) (7) (5.5) (7.5) (4) (4.5)
n=5 n=5 n=3 n=6 n=3 n=4
5h 18.5 12* 21.5 13.5* 21.5 11.5**
(7.5) (2.5) (6.5) (4.5) (4.5) (3.5)
n=6 n=6 n=6 n=6 n=6 n=7
24h 14.5 11.5 16 12 15.5 12.5
(4) (7) (4.5) (6) (7) (6)
n=9 n=7 n=6 n=6 n=7 n=8
Fluid communication could not be maintained in all tumours during the 60min experiment, explaining the decreasing
number ofmeasurements during time. Numbers in parentheses are standard deviations. *P<0.05. **P<0.01.Effect of TNF-a on interstitial fluid pressure
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Table II Mean arterial blood pressure, respiration rate and blood gas analysis performed 5 and 24h after injection of
TNF-a (500pg kg'l) or sodium chloride (controls)
5h 24h
Sodium chloride TNF-a Sodium chloride TNF-a
MABP (mmHg) 111.1 78.6** 100.4 106.3
(14.8) (22.9) (19.9) (17.3)
n=18 n=20 n=23 n=19
Respiration rate 88 80 98 95
(22) (20) (21) (18)
Blood gas analysis
pH 7.15 7.07* 7.19 7.18
(0.04) (0.08) (0.06) (0.09)
pCO2 (mmHg) 58.8 51.6* 52.2 51.8
(4.8) (5.9) (6.8) (9.8)
P02 (mmHg) 79.1 81.8 61.8 71.1
(15.6) (17.2) (9.7) (18.3)
[HCO31 19.6 14.4** 19.5 19.0
(2.2) (2.8) (3.3) (3.4)
Numbers in parentheses are standard deviations. *P<0.05. **P<0.01.
represents the main mechanism for the IFP reduction, but
an actual increase in the pressure gradient across the vessel
wall cannot be excluded by the present data. Thus, the
previously demonstrated increase in antibody uptake 1-4 h
after i.v. TNF-a injection (Folli et al., 1993; Rowlinson-
Busza et al., 1995) might still be explained by an increase in
vascular permeability surface area product and/or convec-
tion across the microvascular wall.
Both groups (TNF-a-treated and controls) were acidotic,
presumably owing to the anaesthesia and the dorsal positon
of the mouse during the cannulation surgery, which reduces
the respiration rate of the animals (Y Boucher, unpublished
observation). The further decrease in plasma pH 5 h after
TNF-a injection compared with controls was accompanied by
a decrease in bicarbonate concentration and pCO2, indicating
a partially compensated metabolic acidosis, as has been
described previously in relation to hypotension after systemic
TNF-a treatment (Kettelhut et al., 1987).
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